Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Intensity Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- 0 vs. Q3 2024
- Shares held
- 2.72M
- +980.1K (+56.3%) vs. Q3 2024
- Total value
- $4.79M
- −$1.86M (−27.9%) vs. Q3 2024
- New holders
- 3
- 4 more added
- Sold out
- 3
- 5 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INTS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $4.79M |
| Q1 2026 | 14 | $1.06M |
| Q4 2025 | 35 | $1.58M |
| Q3 2025 | 26 | $721.2K |
| Q2 2025 | 27 | $606.6K |
| Q1 2025 | 21 | $5.10M |
| Q4 2024 | 20 | $4.79M |
| Q3 2024 | 20 | $6.65M |
| Q2 2024 | 23 | $8.23M |
| Q1 2024 | 18 | $8.49M |
| Q4 2023 | 17 | $4.39M |
| Q3 2023 | 10 | $1.19M |
| Q2 2023 | 2 | $170.2K |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Intensity Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 1,126,868 | $1.98M | 0.05% | +1,126,868 | New |
| Sapient Capital LLC | 942,841 | $1.66M | 0.03% | −67,912−6.7% | Reduced |
| Vanguard Group Inc | 208,886 | $369.7K | 0.00% | 00.0% | Unchanged |
| Brown Advisory Inc | 130,072 | $228.9K | 0.00% | −18,037−12.2% | Reduced |
| Geode Capital Management, LLC | 64,349 | $113.9K | 0.00% | 00.0% | Unchanged |
| Sigma Planning Corp | 54,837 | $96.5K | 0.00% | +7,093+14.9% | Added |
| Blair William & Co | 37,805 | $66.5K | 0.00% | 00.0% | Unchanged |
| One Charles Private Wealth Services, LLC | 31,800 | $56.0K | 0.02% | 00.0% | Unchanged |
| BlackRock, Inc. | 22,252 | $39.2K | 0.00% | +139+0.6% | Added |
| Mesirow Financial Investment Management, Inc. | 20,000 | $35.2K | 0.00% | −24,177−54.7% | Reduced |
| GTS Securities LLC | 19,030 | $33.7K | 0.00% | −18,258−49.0% | Reduced |
| Lakeview Capital Partners, LLC | 17,420 | $30.7K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 14,964 | $26.5K | 0.00% | +14,964 | New |
| State Street Corp | 14,500 | $25.7K | 0.00% | 00.0% | Unchanged |
| Stonebridge Financial Group, LLC | 8,301 | $14.6K | 0.00% | +8,301 | New |
| UBS Group AG | 3,021 | $5.32K | 0.00% | −17,588−85.3% | Reduced |
| Tower Research Capital LLC (TRC) | 2,648 | $4.66K | 0.00% | +1,479+126.5% | Added |
| Morgan Stanley | 500 | $880 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 50 | $88 | 0.00% | +1+2.0% | Added |
| JPMorgan Chase & Co | 17 | $30 | 0.00% | 00.0% | Unchanged |
| Sentinus, LLC | 0 | $0 | 0.00% | −18,918−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −10,414−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −3,450−100.0% | Sold out |